News Headlines Article

Why Pfizer pulled plug on failed Alzheimer’s drug trial
USA Today

Pfizer Inc.’s decision to pull the plug this week on an experimental drug for Alzheimer’s disease was a disappointment, but not a big surprise, say medical experts eager for a breakthrough. The company said Monday that the trial of bapineuzumab is being stopped in patients with mild to moderate symptoms after it failed to change cognitive and functional performances.